Enliven Therapeutics priced an upsized public offering of 8,933,334 common shares at $37.50 and pre-funded warrants for 1,733,333 shares at $37.499, targeting gross proceeds of about $400 million before fees. Underwriters hold a 30-day option to purchase up to 1.6 million additional shares at the same public offering price.
Enliven Therapeutics launched an upsized underwritten offering comprising 8,933,334 common shares at $37.50 each and pre-funded warrants allowing holders to acquire up to 1,733,333 additional shares at $37.499 apiece, with a nominal $0.001 exercise price per warrant.
The offering is expected to generate approximately $400.0 million in gross proceeds before underwriting discounts, commissions and offering expenses, and is scheduled to close on or about June 15, 2026, subject to customary closing conditions.
Underwriters have a 30-day option to purchase up to 1,600,000 additional common shares at the public offering price less discounts and commissions. Jefferies, Goldman Sachs, Morgan Stanley and Barclays serve as joint book-running managers, with Mizuho and LifeSci Capital in supporting roles and Baird and Jones also participating in the syndicate.
